Clinical trial
A Randomized, Double-Blind, Multicenter, Parallel-Group Comparative Phase III Study Evaluating the Efficacy and Safety of TAK-816 Compared With ActHIB in Healthy Infants
NCT01379846 is registered in ClinicalTrials.gov with Takeda as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Multicenter, Parallel-Group Comparative Phase III Study Evaluating the Efficacy and Safety of TAK-816 Compared With ActHIB in Healthy Infants
- Lead sponsor
- Takeda
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2011
- Completion date
- February 28, 2013
- Enrollment
- 416 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.
immunization